The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Research Report 2025
Synopsis
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.
The global Epidermal Growth Factor Receptor (EGFR) Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The high efficacy of EGFR inhibitors in the treatment of various types of cancer indications has encouraged researchers to study its use in the treatment of inflammatory and monogenic diseases. Recent in-vitro research studies have suggested that EGFR mutations may cause indications such as eczema, psoriasis, and atherosclerosis. Although these studies are in the early stages of clinical trials, the huge unmet need and further advancements in research are expected to brighten the growth prospects of EGFR inhibitors market vendors in new research areas.
This report aims to provide a comprehensive presentation of the global market for Epidermal Growth Factor Receptor (EGFR) Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Epidermal Growth Factor Receptor (EGFR) Inhibitor.
Report Scope
The Epidermal Growth Factor Receptor (EGFR) Inhibitor market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Epidermal Growth Factor Receptor (EGFR) Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen Inc.
AstraZeneca Plc
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd.
Novartis AG
Segment by Type
Lung Cancer
Colorectal Cancer
Breast Cancer
Others
Segment by Application
Hospital
Research Institutes and Research Institutions
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Epidermal Growth Factor Receptor (EGFR) Inhibitor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.
The global Epidermal Growth Factor Receptor (EGFR) Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The high efficacy of EGFR inhibitors in the treatment of various types of cancer indications has encouraged researchers to study its use in the treatment of inflammatory and monogenic diseases. Recent in-vitro research studies have suggested that EGFR mutations may cause indications such as eczema, psoriasis, and atherosclerosis. Although these studies are in the early stages of clinical trials, the huge unmet need and further advancements in research are expected to brighten the growth prospects of EGFR inhibitors market vendors in new research areas.
This report aims to provide a comprehensive presentation of the global market for Epidermal Growth Factor Receptor (EGFR) Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Epidermal Growth Factor Receptor (EGFR) Inhibitor.
Report Scope
The Epidermal Growth Factor Receptor (EGFR) Inhibitor market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Epidermal Growth Factor Receptor (EGFR) Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen Inc.
AstraZeneca Plc
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd.
Novartis AG
Segment by Type
Lung Cancer
Colorectal Cancer
Breast Cancer
Others
Segment by Application
Hospital
Research Institutes and Research Institutions
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Epidermal Growth Factor Receptor (EGFR) Inhibitor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Lung Cancer
1.2.3 Colorectal Cancer
1.2.4 Breast Cancer
1.2.5 Others
1.3 Market by Application
1.3.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Research Institutes and Research Institutions
1.3.4 Clinic
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Perspective (2019-2030)
2.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Growth Trends by Region
2.2.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Historic Market Size by Region (2019-2024)
2.2.3 Epidermal Growth Factor Receptor (EGFR) Inhibitor Forecasted Market Size by Region (2025-2030)
2.3 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Dynamics
2.3.1 Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Trends
2.3.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Drivers
2.3.3 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Challenges
2.3.4 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Epidermal Growth Factor Receptor (EGFR) Inhibitor Players by Revenue
3.1.1 Global Top Epidermal Growth Factor Receptor (EGFR) Inhibitor Players by Revenue (2019-2024)
3.1.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share by Players (2019-2024)
3.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue
3.4 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Concentration Ratio
3.4.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue in 2023
3.5 Epidermal Growth Factor Receptor (EGFR) Inhibitor Key Players Head office and Area Served
3.6 Key Players Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Solution and Service
3.7 Date of Enter into Epidermal Growth Factor Receptor (EGFR) Inhibitor Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Epidermal Growth Factor Receptor (EGFR) Inhibitor Breakdown Data by Type
4.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Historic Market Size by Type (2019-2024)
4.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Forecasted Market Size by Type (2025-2030)
5 Epidermal Growth Factor Receptor (EGFR) Inhibitor Breakdown Data by Application
5.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Historic Market Size by Application (2019-2024)
5.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (2019-2030)
6.2 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2019-2024)
6.4 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (2019-2030)
7.2 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2019-2024)
7.4 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (2019-2030)
8.2 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Region (2019-2024)
8.4 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (2019-2030)
9.2 Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2019-2024)
9.4 Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (2019-2030)
10.2 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2019-2024)
10.4 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Detail
11.1.2 Amgen Inc. Business Overview
11.1.3 Amgen Inc. Epidermal Growth Factor Receptor (EGFR) Inhibitor Introduction
11.1.4 Amgen Inc. Revenue in Epidermal Growth Factor Receptor (EGFR) Inhibitor Business (2019-2024)
11.1.5 Amgen Inc. Recent Development
11.2 AstraZeneca Plc
11.2.1 AstraZeneca Plc Company Detail
11.2.2 AstraZeneca Plc Business Overview
11.2.3 AstraZeneca Plc Epidermal Growth Factor Receptor (EGFR) Inhibitor Introduction
11.2.4 AstraZeneca Plc Revenue in Epidermal Growth Factor Receptor (EGFR) Inhibitor Business (2019-2024)
11.2.5 AstraZeneca Plc Recent Development
11.3 Eli Lilly and Co.
11.3.1 Eli Lilly and Co. Company Detail
11.3.2 Eli Lilly and Co. Business Overview
11.3.3 Eli Lilly and Co. Epidermal Growth Factor Receptor (EGFR) Inhibitor Introduction
11.3.4 Eli Lilly and Co. Revenue in Epidermal Growth Factor Receptor (EGFR) Inhibitor Business (2019-2024)
11.3.5 Eli Lilly and Co. Recent Development
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 F. Hoffmann-La Roche Ltd. Company Detail
11.4.2 F. Hoffmann-La Roche Ltd. Business Overview
11.4.3 F. Hoffmann-La Roche Ltd. Epidermal Growth Factor Receptor (EGFR) Inhibitor Introduction
11.4.4 F. Hoffmann-La Roche Ltd. Revenue in Epidermal Growth Factor Receptor (EGFR) Inhibitor Business (2019-2024)
11.4.5 F. Hoffmann-La Roche Ltd. Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Epidermal Growth Factor Receptor (EGFR) Inhibitor Introduction
11.5.4 Novartis AG Revenue in Epidermal Growth Factor Receptor (EGFR) Inhibitor Business (2019-2024)
11.5.5 Novartis AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
